Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 8Mitoxantrone 5fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3Filgrastim 3Etoposide 3Cyclophosphamide 3Busulfan 3Bortezomib 3Vorinostat 2Tacrolimus 2Methotrexate 2Decitabine 2tanespimycin 1ixazomib 1fludarabine 1entinostat 1eltrombopag 1choline magnesium trisalicylate 1alvocidib 1Whole-Body Irradiation 1Thiotepa 1Sorafenib 1Proteasome Inhibitors 1Pravastatin 1Mycophenolic Acid 1Metformin 1Lenalidomide 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Erythroblastic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡